AQP4-mediated glymphatic clearance: Sleep, neurodegeneration, and the translational gap.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic, animal, and observational literature without systematic review methodology.
PubMed 42288169 · doi:10.1016/j.neubiorev.2026.106819
What was done
Narrative review synthesizing evidence on astrocytic aquaporin-4 (AQP4)-mediated glymphatic clearance, the bidirectional relationship between slow-wave sleep disruption and neurotoxic protein accumulation (amyloid-beta, tau, alpha-synuclein), and chronic conditions that suppress slow-wave sleep (such as obstructive sleep apnea, chronic obstructive pulmonary disease, and tinnitus). The authors critically evaluated therapeutic strategies to enhance glymphatic function, including slow-wave sleep augmentation, AQP4 restoration, noradrenergic tone reduction, and cerebrospinal fluid flow augmentation.
What was found
The abstract reports no quantitative data or effect sizes. It notes that glymphatic clearance operates predominantly during slow-wave sleep and is impaired across Alzheimer's disease, Parkinson's disease, traumatic brain injury, and normal aging. The authors identify potential self-amplifying cycles where clearance failure accelerates protein accumulation, while noting that causal directionality in humans remains unestablished prospectively.
Why it matters
The review frames sleep disruption as a potential population-scale driver of neurodegenerative disease through glymphatic failure. It highlights that the absence of validated non-invasive glymphatic biomarkers remains a major translational bottleneck.
Limits
As a narrative review, it presents no original empirical data, systematic search methodology, or quantitative pooling. Much of the underlying evidence relies on animal models, post-mortem tissue, and indirect neuroimaging proxies, leaving prospective causal relationships in humans untested.